iwCLL 2019: Dr. Andy Rawstron on minimal residual disease (MRD) testing for chronic lymphocytic leukemia (CLL) iwCLL 2019: Dr. Andy Rawstron on minimal residual disease (MRD) testing for chronic lymphocytic leukemia (CLL)... September 24, 20202019 Conferences, MRD & Disease MonitoringBy Brad Hedrick
ASH 2019: Dr. Brian Koffman on our Expert Access™ Program for patients with chronic lymphocytic leukemia (CLL) ASH 2019: Dr. Brian Koffman on our Expert Access™ Program for patients with chronic lymphocytic leukemia (CLL) ... September 17, 20202019 ConferencesBy Brad Hedrick
ASH 2019: Dr. Neil Kay on Ibrutinib and Rituximab for Chronic Lymphocytic Leukemia (CLL) The ECOG (E1912) Phase III, randomized, open label, clinical trial, comparing the efficacy of combination ibrutinib and rituximab with standard... September 10, 20202019 ConferencesBy Brad Hedrick
ASH 2019 MRD Testing: Dr. Chaitra Ujjani’s short video explains the concept of MRD testing and its value in predicting progression free survival. ASH 2019 MRD Testing: Dr. Chaitra Ujjani’s short video explains the concept of MRD testing and its value in predicting... August 27, 20202019 Conferences, MRD & Disease MonitoringBy Brad Hedrick
ASCO 2020 “Top 12” #1: Fixed-duration venetoclax-obinutuzumab for previously untreated patients with chronic lymphocytic leukemia: Follow-up of efficacy and safety results from the multicenter, open-label, randomized, phase III CLL14 trial ASCO 2020 "Top 12" #1: Fixed-duration venetoclax-obinutuzumab for previously untreated patients with chronic lymphocytic leukemia: Follow-up of efficacy and safety... August 26, 20202020 ConferencesBy Brad Hedrick
ASH 2019: Dr. Parikh Discusses Clinical Trial of Early Intervention in High-Risk CLL Patients ASH 2019, Dr. John Pagel interviews Dr. Sameer Parikh regarding a clinical trial out of all locations of the Mayo... August 20, 20202019 ConferencesBy Brad Hedrick
ASH 2019: Dr. Furman Discusses Bruton’s Tyrosine Kinase Inhibitors Evolution ASH 2019 Drs. Brian Koffman and Richard Furman discuss the effectiveness and tolerability of covalent irreversible BTK inhibitors such as... August 20, 20202019 ConferencesBy Brad Hedrick
ASCO 2020 “Top 12” #2: Acalabrutinib in treatment-naïve chronic lymphocytic leukemia: Mature results from phase II study demonstrating durable remissions and long-term tolerability #2 At virtual ASCO 2020, Dr. John Byrd led a group of researchers to report the latest from the first... August 20, 20202020 ConferencesBy Brad Hedrick
ASH 2019: Dr. Anthony Mato on LOXO-305 for Chronic Lymphocytic Leukemia (CLL) During this ASH 2019 interview, Dr. Anthony Mato discusses data he presented on LOXO-305. This selective, reversible (non-covalent) BTK inhibitor... August 15, 20202019 ConferencesBy Brad Hedrick
ASH 2019: Dr. Paul Barr on the combination of umbralisib, ublituximab, and venetoclax for treatment of chronic lymphocytic leukemia (CLL) ASH 2019: Dr. Paul Barr on the combination of umbralisib, ublituximab, and venetoclax for treatment of chronic lymphocytic leukemia (CLL)... August 3, 20202019 ConferencesBy Brad Hedrick
